Tianfu Wen
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 140 publications
Underrecognized cardiovascular complications after hepatectomy: population-level mortality burden from a multicentre population-attributable fraction (PAF) analysis.
Journal: Bioscience trends
Published: August 03, 2026
Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review.
Journal: Frontiers in oncology
Published: January 29, 2026
Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
Journal: The oncologist
Published: October 22, 2025
PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.
Journal: Future oncology (London, England)
Published: October 21, 2025
Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Journal: Bioscience trends
Published: August 03, 2025
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
Journal: Lancet (London, England)
Published: July 24, 2025
A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.
Journal: Langenbeck's archives of surgery
Published: April 26, 2025
Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).
Journal: Hepatobiliary surgery and nutrition
Published: February 28, 2025
Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study.
Journal: Journal of hepatocellular carcinoma
Published: January 08, 2025
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
Journal: Bioscience trends
Published: December 25, 2024
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: November 13, 2024
Last Updated: 09/26/2026